









Litfalls and limitations in measuring and interpreting the
utcomes of mitral valve repair
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doi:10.1016/j.jtcvs.2005.11.033n this edition of the journal, Serri and colleagues1 present their midterm results
of valve repair for ischemic mitral regurgitation. They observed significant
mitral regurgitation in over half of their patients during the follow-up period,
hich averaged 28 months, and implied the need for alternative repair techniques or
ore mitral valve replacement. This is in line with other recent studies that have also
hown a high rate of recurrence of mitral regurgitation after annuloplasty for
schemic mitral regurgitation.2-5 Can this justification be reliably drawn? Are
urrent approaches to repair ineffective in a significant number of patients with
schemic mitral regurgitation? Can their results be extrapolated to other centers
ndertaking repair of ischemic mitral regurgitation? We would argue that the study
f Serri and colleagues1 displays several common clinical and methodologic pitfalls
hat limit generalization of results from most studies of mitral valve repair. Below,
e outline specific challenges in measuring and reporting outcomes of mitral valve
epair. Although we illustrate these using the study of Serri and colleagues,1 the
itfalls are not unique to their study and apply to varying degrees in all studies of
itral valve repair. Knowledge of these pitfalls is necessary to improve the quality
f outcomes-based research on mitral valve repair, to allow accurate interpretation
f these studies, and also to permit useful extrapolation of results.
efining a Patient Cohort
erri and colleagues1 defined ischemic mitral regurgitation as “mitral regurgitation
esulting from prior myocardial infarction associated with normal mitral valve
eaflets and chordae.” This is an etiologic definition that fails to take into account the
alve dysfunction or the lesions that actually result in the mitral regurgitation. What
s a “normal mitral leaflet”? Carpentier’s pathophysiologic triad describes the
nterrelationship between leaflet motion (dysfunction), lesions, and etiology.6 Car-
entier’s classification of dysfunction is based on the opening and closing motions
f the mitral leaflets in relation to the annular plane. Most patients with ischemic
itral regurgitation have type IIIb leaflet dysfunction, with restricted leaflet motion
n systole. Wall motion abnormalities, associated with left ventricular dilatation and
ateral or apical papillary muscle displacement, result in this type of valve dysfunc-
ion. The lesion associated with type IIIb dysfunction is primarily leaflet tethering,
specially the posterior-medial scallop of the posterior leaflet (P3). Associated
nnular dilatation may be present, but leaflet tethering is considered the primary
esion. Type I dysfunction (normal leaflet motion) with isolated annular dilatation is
ess common but may occur in the setting of basal myocardial infarction. Some
atients with ischemic mitral regurgitation have type II (excess leaflet motion)
ysfunction. The lesions resulting in type II ischemic mitral regurgitation include an
cutely ruptured papillary muscle or a previously infarcted fibrotic and elongated
apillary muscle. In rare instances, isolated chordal rupture can also be seen
ollowing papillary tip ischemia.
We advocate a more uniform methodology to classify mitral valve cohorts not
nly on the basis of etiology but inclusive of dysfunctions and lesions. The
mportance of such an approach is well demonstrated in ischemic mitral regurgita-
ion. The majority of patients have type IIIb dysfunction, and a remodeling annu-
oplasty must be undersized to overcorrect the septal-lateral dimension and achieve
n adequate surface of leaflet coaptation. Patients with ischemic mitral regurgitation











































































































Lnd leaflet restriction (type IIIb dysfunction) are more likely
o have residual leaks compared with patients with type I
ysfunction who have normal leaflet motion and are treated
n a similar fashion. Furthermore, patients with ischemic
itral regurgitation and type II dysfunction have a better
ong-term prognosis than those with type IIIb dysfunction.7
hus it is inadequate to describe a population of patients
ith ischemic mitral regurgitation solely on the basis of
tiology. This point is equally valid in patients with a
degenerative” etiology of mitral valve disease. Prolapse
type II dysfunction) of the posterior leaflet due to a
ingle ruptured chord (isolated lesion) has a markedly
ifferent repair rate and long-term freedom from recur-
ent mitral regurgitation compared with bileaflet prolapse
ith chordal rupture and/or elongation involving multiple
eaflet segments. Definition of a population of mitral valve
atients on the basis of etiology, dysfunction, and lesions is
ecessary to allow adequate comparison of outcomes, as all
an impact clinical results.
ariations in Surgical Techniques
o extrapolate the efficacy of a surgical technique in a
urrent article to contemporary practice, it is important that
he reader determine whether the technique under evalua-
ion was applied in a standardized and systematic manner
hat upholds current principles and understanding of patho-
hysiology. This is particularly relevant in mitral valve
epair surgery, as the quality of the result judged by residual
r recurrent mitral regurgitation is largely dependent on the
anner in which the repair has been performed. For exam-
le, it is now well accepted that in the setting of type IIIb
ysfunction, patients with ischemic mitral regurgitation
hould receive an undersized ring to overcorrect the septal-
ateral dimension and ensure an adequate surface of coap-
ation between tethered leaflets.8,9 As Serri and colleagues1
o not appear to have undertaken valve sizing in any stan-
ardized or logical fashion, their results cannot define the
urrent efficacy of ischemic mitral valve repair. Their stated
pproach to sizing “that men or large patients tended to
eceive a 28 mm ring while women or smaller patients
ended to receive a 26 mm ring” does not have a scientific
oundation and indeed is not borne out by their own data, as
third of the patients received neither of these ring sizes.
urthermore, although the authors state rings were under-
ized, 2% got a 34-mm ring and 7% a 32-mm ring—this
mplies that in 9% of cases the true size was at least 34 mm.
uch a large anterior leaflet surface area would be unusual
n patients with IIIb dysfunction and suggests that either the
ings may not have been sized appropriately or the etiology
as not ischemic. Because it is now widely accepted that
se of an appropriately downsized ring is the single most
mportant aspect of mitral repair for ischemic mitral regur-
itation, the absence of a precise sizing technique raises t
24 The Journal of Thoracic and Cardiovascular Surgery ● Marcoubts regarding surgical approach and could explain their
uboptimal long-term results.
The use of incomplete flexible posterior annular bands
in 10% of patients) further complicates interpretation of
heir results. Recent articles have linked flexible posterior
ands with significant recurrent ischemic mitral regurgita-
ion.2,4 It is now well established that patients with ischemic
itral regurgitation can develop dilatation of the anterior
nnulus between the trigones.10,11 Because posterior flexi-
le bands do not correct intertrigonal dilatation, they may
ot effectively ensure restoration of an adequate surface of
eaflet coaptation. In combination with an inconsistent
ethodology for ensuring proper downsizing of all of the
rostheses used in this study (whether partial band or com-
lete ring), these issues raise a significant concern that
aried surgical approaches contributed to the suboptimal
esults.
hat Are Acceptable Early Results for Mitral
alve Repair?
good long-term outcome follows a low operative mortal-
ty (patients have to survive to experience a long-term
utcome) and a satisfactory early surgical result (an opera-
ion not successful in the short term will remain unsuccess-
ul). Only series with good early results optimally define the
ong-term efficacy of a surgical procedure. Suboptimal early
esults in a cohort of mitral valve repairs suggests that
dequate operations have not been performed; it is not ideal
o define long-term outcomes of repair from such a series.
here are presently no guidelines that define standards for
n acceptable valve repair. Differing quality and standards
or mitral valve repair in different institutions impact long-
erm outcomes, making the literature even more difficult to
nterpret. This differs from other forms of valve surgery
here the prosthesis, rather than the surgical technique
tself, is the primary determinant of long-term outcome.
Residual mitral regurgitation. Significant residual mi-
ral regurgitation following valve repair, documented ei-
her on postbypass transesophageal echocardiography
TEE) or predischarge transthoracic echocardiography,
mplies an immediate failure of the technique employed. In
uch cases the valve repair was really never successful, and
t is not surprising that regurgitation persists into the long
erm. It would be incorrect to label such cases as “recurrent”
itral regurgitation in studies of long-term outcomes, as the
itral regurgitation was never eliminated at surgery. In the
ame way that recurrent cancer can only be defined when
he primary tumor was successfully and completely re-
ected, recurrent mitral regurgitation should be defined only
hen surgery initially eliminated the mitral regurgitation.
hese definitions are often not clarified, and residual mitral
egurgitation may account for a substantial proportion of
recurrent” mitral regurgitation reported after ischemic mi-













































































































Led 30 patients with “recurrent” mitral regurgitation after
nnuloplasty for ischemic mitral regurgitation in an attempt
o understand the mechanisms of recurrence, yet 30% of
hese patients had moderate or severe mitral regurgitation
n the early postoperative study and should have been
ategorized with residual mitral regurgitation.
Surgeons generally should not accept any degree of
itral regurgitation other than trivial or mild on the post-
ypass TEE, as the freedom for need of reoperation, reverse
entricular remodeling, and resulting improvements in qual-
ty of life are at least in part dependent on elimination of
itral regurgitation. Significant degrees of residual mitral
egurgitation (moderate to severe mitral regurgitation and
ometimes even mild mitral regurgitation) should generally
rigger a second bypass run and corrective action (for ex-
mple, further ring downsizing, leaflet patch extension, cor-
ection of unrecognized prolapse, or valve replacement).
his need for a second bypass run should be uncommon and
robably not exceed 5% as mitral regurgitation should be
liminated in most patients with correct ring choice and
izing. Only in exceptional circumstances should patients
eave the operating room with residual moderate mitral
egurgitation; such as when a valve is deemed irreparable
nd nonreplaceable (eg, massive atrial/annular calcification)
r when the risks of a second bypass run are thought to
utweigh the benefits. In the study by Serri and colleagues,1
0.6% of patients had moderate mitral regurgitation on the
ostbypass TEE; all were left uncorrected. The authors did
ot clarify the reason for the high incidence of residual
oderate mitral regurgitation and why it was left uncor-
ected. A 10% residual mitral regurgitation rate for ischemic
itral valve repair suggests a problem with the repair tech-
ique as moderate mitral regurgitation immediately post-
ypass should be uncommon. For example, Glower and
olleagues had only 1 patient with more than mild mitral
egurgitation on the postbypass TEE in a series of 141
epairs for ischemic mitral regurgitation using downsized
emirigid complete rings.12 If patients leave the operating
oom with significant mitral regurgitation, then the repair
as failed by definition and therefore will also fail in the
ong term. Indeed, of the 7 patients in the current series who
ad moderate residual mitral regurgitation, 4 either died or
equired mitral valve replacement in the early postoperative
hase.1 Any study with a high degree of residual mitral
egurgitation may be relied on to define perioperative but
ot long-term outcomes of mitral valve repair.
Adverse events (mortality and morbidity). Although
ombined mitral valve surgery and coronary artery bypass
as historically associated with high morbidity and mortal-
ty, contemporary series from expert centers report mortal-
ty rates in the range of 4% to 7%.12-14 The operative
ortality reported by Serri and associates1 of 12.3% isomewhat higher than other recent series, and although the g
The Journal of Thoracicuthors describe their early postoperative results as “very
ood,” it is important to emphasize that in a contemporary
ractice experienced in mitral valve repair, mortality rates in
he region of 5% should be attainable in patients with
schemic mitral regurgitation.
Indicators of quality. Early results after mitral valve
urgery are probably an indirect indicator of the quality of a
epair program. Markers of quality include mortality, mor-
idity, and echocardiographic indicators of successful repair
such as lack of residual mitral regurgitation). The better the
arly results, the more likely it is that mitral repair has been
ffectively applied and the greater likelihood that repairs
ill be durable and effective in the long term. Deficient
arly results may partly be an indication that repair tech-
iques have not been applied optimally; if that is the case,
hen long-term results too will be compromised. Indeed,
ndicators of quality of mitral valve repair appear interre-
ated, such that performance on one indicator is likely to
ransform to similar performance on all fronts. For example,
he early results by Serri and colleagues1 are somewhat
ompromised by both a high residual mitral regurgitation
ate and relatively high mortality, and later follow-up found
ignificant recurrent mitral regurgitation and no reverse
emodeling of the left atrium or left ventricle. The interre-
ation of quality indicators is also well illustrated by the
eries of Bax and colleagues,15 who stringently downsized
omplete semirigid rings in 51 patients with ischemic mitral
egurgitation and reported a 5.6% operative mortality, 84%
urvival at 2 years, significant reduction in left ventricular
nd left atrial dimensions at 2 years, and no residual or
ecurrent moderate mitral regurgitation. Thus, consistent
ractice and good early outcomes are more likely to trans-
orm to a sustainable repair. Requisite to defining the bench-
ark for long-term outcome of mitral repair should there-
ore be a good performance on early quality indicators and
practice that reflects contemporary concepts in the litera-
ure (ring type used, median ring size, residual mitral re-
urgitation rate, operative mortality).
ncomplete Echocardiographic Data
ommon to almost all studies of mitral valve repair is
ncomplete availability of echocardiographic data. Com-
lete echocardiographic data at the key time points (preop-
rative, postbypass, predischarge, early postoperative, and
ate postoperative) is the exception rather than the rule. In a
eries of 585 ischemic mitral valve repairs between 1985
nd 2002 reported by McGee and colleagues2 from Cleve-
and Clinic Foundation (the specialty leader in outcomes-
ased research), preoperative echocardiograms were not
vailable for review in 18% of patients, and postoperative
tudies were unavailable in 25% of patients. For most cen-
ers an even greater proportion of unavailable echocardio-
rams is likely. Probably prompted by the paucity of good







































































































Lchocardiogram data, several studies on repair for ischemic
itral regurgitation use mortality or reoperation as out-
omes, but survival is a weak surrogate for recurrent mitral
egurgitation, as is the reoperation rate.
The lack of complete echocardiographic data makes it
ore difficult to draw conclusions about successfulness of
itral valve repair. In the study by Serri and colleagues,1
he paucity of echo data forced the authors to combine
ostbypass TEE and predischarge echocardiography as a
ingle measurement. It is well established that intraopera-
ive TEE may underestimate mitral regurgitation because of
nloading related to anesthesia.16,17 Predischarge studies
re therefore preferable in establishing a postrepair baseline
chocardiogram. Serri and colleagues1 also grouped all mid-
erm echocardiograms without incorporating the varying
ime periods to recurrence of mitral regurgitation. Indeed,
nly 18 patients were included in the detailed echocardio-
raphic analysis, a subset too small to allow useful extra-
olation. Combining the data in this form is often necessary
ue to high levels of missing or incomplete data but reduces
he validity of the results.
Problems with echocardiographic data will likely persist
n future reports, as in many institutions, costs, and logistics
ake it impractical to obtain regular follow-up echocardi-
graphy for all patients. Nonetheless, longitudinal studies
hat include regular echocardiography follow-up will be the
old standard to define the true efficacy of mitral valve
epair procedures and should be pursued.
ethodologic Limitations
ow Case Volume and Long Study Periods
n most centers, surgery for ischemic mitral regurgitation
epresents only a small percentage of the overall cardiac
urgery. Due to low case volume, sufficient numbers for
nalysis can only be achieved if studies span long time
eriods. Even well-established valve centers may have dif-
culty accruing large numbers of ischemic mitral regurgi-
ation patients, as reflected in the current series reported by
erri and colleagues,1 which averaged about 11 ischemic
itral repairs per year. Reports spanning long periods (in
he case of Serri and associates,1 from 1996 to 2002), which
nclude evolution in surgical understanding, experience, or
echnique, necessarily produce biased results. Cases done
arly in the series (when the techniques and protocols have
ot been mastered and perfected) are more prone to subop-
imal results, yet are those more likely to have the longest
ollow-up. The long-term follow-up therefore often reflects
n earlier (learning) era rather than a contemporary (estab-
ished) one. This is less important for well-established tech-
iques like mitral valve replacement but may significantly
ias reports of evolving techniques such as valve repair in
schemic mitral regurgitation. c
26 The Journal of Thoracic and Cardiovascular Surgery ● MarcBias due to combination of different eras is well illus-
rated by the study of McGee and colleagues.2 Among their
ndings was an observation that there was no difference in
ecurrent mitral regurgitation rates between the Carpentier-
dwards Classic complete semirigid ring (Edwards Life-
ciences, Irvine, Calif), and the Cosgrove-Edwards flexible
and (Edwards Lifesciences). Aside from the changes in
edical science and perioperative care over the 17 year
tudy period, a notable source of bias is that choice of
nnuloplasty ring in that series was heavily dependent on
ra, as was the approach to downsizing. Early in the series,
ost patients received Carpentier-Edwards Classic rings
nd from 1997 most patients received Cosgrove-Edwards
ands. As the importance of downsizing was not appreci-
ted until the late 1990s, there was no systematic downsiz-
ng of the Carpentier-Edwards subgroup, whereas most
osgrove-Edwards bands were undersized (the median ring
ize was 30 mm for Carpentier-Edwards rings compared
ith 26 mm for Cosgrove-Edwards bands). Their analysis
herefore favors the Cosgrove-Edwards subgroup because
hey were performed in a more recent era, hence benefiting
rom modern approaches to management, and also had a
pecific therapy for ischemic mitral regurgitation (downsiz-
ng) that was absent in the Carpentier-Edwards group. Con-
ersely their observation that size of annuloplasty was not
redictive of recurrence of mitral regurgitation was con-
ounded because larger rings were generally complete and
emirigid and smaller rings were generally flexible band.
he inconsistent use of downsized complete semirigid rings
robably resulted in underestimation of the long-term effi-
acy of annuloplasty for ischemic mitral regurgitation in
hat study.
This problem of a long heterogeneous study period is
ommon to most studies of valve repair and results in
nderestimation of the efficacy of repair. The problems of
ow case volume and era-associated knowledge and practice
ifferences can be partly overcome by pooling multicenter
ata over a short period of time.
Retrospective study design. Most clinical cardiac surgi-
al research is understandably based on retrospective data.18
retrospective study design per se is not a major limitation;
ndeed, most of the evidence on which we base our practice
s derived from such studies. Mitral valve repair, however,
resents unique circumstances that limit the usefulness of
his study method. Much of the information crucial to un-
erstanding mitral valve repair outcomes can only be ob-
ained prospectively. These include the decision to repair or
eplace, the planned or attempted (as opposed to the com-
leted) repair, the basis for the chosen repair method, spe-
ific intraoperative descriptions of valve lesions and dys-
unction, the basis for selection and sizing of a ring,
chocardiographic measurements specific to the study’s fo-












































































































Legurgitation. Such data are important for examining out-
omes of mitral valve repair and generally are not obtain-
ble from retrospective chart review. The variations in mi-
ral pathology, valve dysfunction, clinical decision making,
nd operative approaches are such that retrospective review
f operative notes will often be inadequate for studies of
alve repair.
Most institutions should now have the database infra-
tructure to prospectively capture critical perioperative data.
enters with an interest in mitral repair should broaden their
atabases, or create specific mitral databases, to include
elevant data on mitral valve echocardiography, pathology,
ysfunction, and surgical repair. Only retrospective analysis
f prospectively collected data (that are entered into a
atabase at time of surgery), or planned prospective studies,
an provide the most robust data on mitral valve repair.
Evolving technology. Another problem highlighted by
erri and associates’ study1 is the difficulty in assessing
volving technologies. Although Serri and colleagues do
ot allude to this, and have presented their data in a manner
uggesting that all patients received the same treatment over
he study period, in reality this could not have been the case
s the understanding and techniques of repair for ischemic
itral regurgitation evolved considerably over the study
eriod. For example, the approach to annuloplasty down-
izing is unlikely to have been consistent. Diodato and
olleagues,14 reporting on outcomes of ischemic mitral re-
urgitation, noted significant changes in practice over a
imilar period; notably, the practice of downsizing evolved
rom only 21% of annuloplasty rings sized 28 mm and
elow in 1996 to 1997 to 95% sized 28 mm and below by
000 to 2001. Such evolving patterns complicate analysis
nd interpretation of data as patients have not received the
ame treatment. Several new annuloplasty devices and mod-
fications of surgical technique have emerged in the last 5
ears and continue to be developed9,19; depending on the
sage of such new technologies (some are beneficial and
ome detrimental), impact on outcome could be substantial.
nvestigators should accommodate for these changes in
ractice such as by analyzing changes in outcome over time
as most practice changes are temporally linked) or by
erforming subgroup analysis to specifically examine the
mpact of new devices and techniques. Changes are, how-
ver, often multiple and are not applied in a systematic
ashion, making analysis and logical deduction difficult.
ulticenter studies with standardized protocols conducted
ver a relatively short time period may minimize the effect
f evolving technology; however, as midterm results of
uch studies are presented, the techniques themselves may
ave become obsolete, due to subsequent arrival of new
echnologies and improved understanding.
Statistical limitations. Analysis of valve-related out-
omes presents specific statistical quandaries because of o
The Journal of Thoracicifficulty in depicting and analyzing time-related change
here there are several competing outcomes (such as death,
alve reoperation, and transplantation). This is further com-
licated where the outcome is graded (mild, moderate, or
evere regurgitation) rather than binary and may change
ver time (to lesser or greater degrees of mitral regurgita-
ion). These issues are well discussed elsewhere, notably by
runkemeier and associates20,21 and Blackstone.22 Obsta-
les to statistical analysis also arise because postoperative
ata (echocardiography in this case) on mitral valve repair
re often derived from clinical assessments made at irreg-
lar intervals for reasons that differ from patient to patient.
n some patients, death, disability, relocation, reoperation,
ransplantation, or a number of nonrandom events (possibly
elated to the valve disease or valve repair) may interrupt
btaining further measurements. A patient who does not
ave any echocardiogram after the first year may well be
edridden in a nursing home with severe heart failure but
ill be assumed to have a (censored) good outcome. Stan-
ard techniques based on censoring may therefore be flawed
ecause censoring is assumed to be noninformative (ie, the
oss to follow-up bears no relationship to the intervention or
utcome). Authors of valve outcome studies have used
arious ways to handle this and generally attempt to over-
implify what is actually a complicated stream of data. For
xample, Serri and colleagues1 analyzed postoperative
chocardiographic data as though they were obtained at the
ame time, grouping together follow-up echocardiograms
btained at any interval from several months to several
ears after surgery. They consolidated these into a single
gure for the incidence of “midterm” mitral regurgitation.
ow does one interpret a figure of 57% moderate to severe
ecurrent mitral regurgitation in the midterm—is that at 1
ear, 3 years, 5 years? This figure also formed the basis of
ultivariate analysis for predictors of postoperative mitral
egurgitation. Such analysis is heavily flawed as occurrence
f mitral regurgitation is a time-related event; mitral regur-
itation at 1 year is substantially different from that occur-
ing at 7 years and thus cannot be combined as though they
re one. How does one deal with long gaps in assessment,
uch as a patient who had no mitral regurgitation on a 1-year
tudy and presents with symptoms 4 years later with echo-
ardiogram showing severe mitral regurgitation? Although
asiest to assume that mitral regurgitation recurred at the
oint of echocardiogram, in reality it may have occurred
everal years earlier.
Even where the outcome measure does not suffer from
rregular and inconsistent measurement intervals (such as
reedom from valve reoperation), conventional actuarial
ethods overestimate the true frequency of valve-related
vents as they assume patients remain at risk of valve failure
fter death (as observations are censored at death).21 Some
f these problems can be overcome with advanced statistical



















































































Lethods that are generally beyond the scope of the clinical
urgeon. These require specialized statistical expertise.22
he problem, however, remains that with most valve out-
ome studies authors prefer to oversimplify the outcomes, in
manner that they can easily analyze and interpret, and in
oing so invariably report inaccurate or inadequate results.
s Blackstone22 puts it “Unfortunately, we insist on doing
ur own statistics, content to live with the simple answers
ather than those that are most revealing or most accurate.”
Serri and colleagues1 also made a significant statistical
rror in their presentation and analysis, which highlights the
ifficulty in using mitral regurgitation grade as an outcome.
n their data summary and analysis, they have treated the
itral regurgitation grade as a continuous variable, deriving
eans, standard deviations, and also using linear regression
o predict recurrent mitral regurgitation. Mitral regurgitation
rade is not, however, a continuous variable but rather a
ategorical variable (or more specifically an ordinal or rank-
rdered variable) and therefore cannot be subjected to math-
matical manipulation. The 4 grades could have just as
asily been labeled I, II, III, and IV or trivial, mild, mod-
rate, and severe. The numerical assignments of 1 to 4 are
rbitrary and made just to illustrate the rank order, rather
han as a quantification or direct measurement of the mitral
egurgitation (grade 4 mitral regurgitation is not twice grade
mitral regurgitation). They have also incorrectly presented
he New York Heart Association (NYHA) class as a con-
inuous variable by summarizing it as a mean and standard
eviation. Data such as NYHA class and mitral regurgita-
ion grade should be summarized using medians or fre-
uency and analyzed as categorical or ordinal variables. The
ack of a quantitative description of mitral regurgitation that
an be uniformly reported on a continuous scale poses
ifficulty in analysis. Authors often resort to categorizing all
itral regurgitation into 2 groups with no discrimination
ased on severity of mitral regurgitation (freedom from
ecurrent mitral regurgitation being freedom from moderate
r severe mitral regurgitation). Echocardiographic quantifi-
ation of mitral regurgitation using a numerical rather than
ualitative description of mitral regurgitation would greatly
implify data analysis.
onclusions
he clinical practice of valve repair presents unique prob-
ems that complicate measurement and analysis of out-
omes. Although we have illustrated this using repair for
schemic mitral regurgitation as presented by Serri and
olleagues,1 the same applies to other valve repair surgery.
lthough it is true that all valve repairs have a long-term
ailure rate, most published series have pitfalls that prevent
ccurate quantification of this rate. To determine the effi-
acy of any mitral repair operation, surgical teams under-
aking studies should have a thorough understanding of
28 The Journal of Thoracic and Cardiovascular Surgery ● Marcathophysiology and apply techniques in a standardized
ashion. Centers undertaking outcome efficacy studies
hould have low postoperative mortality and a documented
ow residual mitral regurgitation rate and should be well
ersed and specialized in mitral repair. To allow later mean-
ngful analysis, data on all valve procedures should be
ollected prospectively in clinical databases and should
nclude relevant perioperative and scheduled postoperative
chocardiographic findings and measurements. Period of
ecruitment for these studies should be relatively short.
ollaborative efforts between different centers are one way
o ensure meaningful recruitment over a period of months
ather than years. At least some valve centers should strive
o obtain scheduled periodic follow-up quantitative echocar-
iography on all patients, as this would markedly simplify
nalysis and interpretation of results. Where the follow-up data
re complex with several repeated measures, high loss to
ollow-up, or competing outcomes, authors should apply
pecialized statistical techniques where indicated rather than
ttempt simplified analysis of data, which will invariably be
rroneous. Only the results of such studies can define, with
elative certainty, the long-term outcomes of mitral valve
epair for ischemic mitral regurgitation or any other mitral
isease.
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